Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City

Abdullah, Khalilda Khaleel; Namik, Muzayyan Fadhly; Khaleel, Iman Ismael

doi:10.21608/ejhm.2023.280209

Study of The Effect of Metformin on Plasminogen Activator Inhibitor-1 (PAI-1) and Some Biochemical and Blood Parameters in Patients with Type 2 Diabetes in Samarra City

Document Type : Original Article

Authors

10.21608/ejhm.2023.280209

Abstract

Background: Metformin, an anti-hyperglycemic drug, treats type 2 diabetes with diet. It increases muscle glucose consumption, maintains blood levels, and does not cause severe hypoglycemia.
Aim: To evaluate the effect of metformin on some plasminogen and cortisol variables and some hematological variables represented in the percentage of compact red blood cells, hemoglobin concentration, total number of red blood cells, and white blood cells in patients with type 2 diabetes.
Subjects and Method: 90 patients with type 2 diabetes and patients who used metformin treatment twice a day continued for three months, six months, and one year were included, according to a questionnaire. After confirming the status of type 2 diabetes through laboratory tests, samples were taken. They were divided into four groups according to the period used in the treatment.
Results: The results indicated that treatment with metformin led to a significant decrease in the level of Plasminogen Activator-1 (PAI-1) and cortisol hormones, in addition, to the decline in hematological indices, packed cell volume (PCV), hemoglobin (Hb), red blood cells (RBCs) and white blood cells (WBCs) within works 2, 3 and 4 compared to the control group.
Conclusion: Metformin may improve the risk of atherosclerotic disease that may occur due to diabetes by lowering blood glucose, such as improving endothelial function, decreasing inflammatory activity, and decreasing blood parameters during treatment, which may be related to anemia.

Keywords